Penn Medicine Reports 30% Drop in Breast Cancer Risk with Ozempic and Wegovy
8 Articles
8 Articles
GLP-1 drugs such as Ozempic or Wegovy are primarily known as weight loss syringes, but they could do even more.
A study led by radiology professor Elizabeth McDonald analyzed the medical records of over 110,000 women aged 45 to 80. The results showed that women using GLP-1 drugs (such as Ozempic and Wegovy) had approximately a 30% lower incidence of breast cancer than non-users; in some statistical models, the risk reduction even reached 35%. The correlation remained after the research team adjusted for age, race, body mass index (BMI), breast density, an…
braunschweiger-zeitung.de
ikz-online.deGLP-1 drugs such as Ozempic or Wegovy are primarily known as weight loss syringes, but they could do even more.
Women taking GLP-1 drugs to lose weight and treat diabetes, including Ozempic, Wegovy, Mounjaro and Zepbound, had an approximately 30% lower risk of developing breast cancer.
Penn Medicine Reports 30% Drop in Breast Cancer Risk with Ozempic and Wegovy
A landmark study published June 2, 2026, in JCO Oncology Practice and simultaneously presented at the 2026 American Society of Clinical Oncology Annual Meeting by researchers at the University of Pennsylvania Perelman School of Medicine has produced findings that could reshape how America’s medical community thinks about GLP-1 receptor agonist drugs and how millions of women with obesity approach their own cancer risk. The study, led by Dr. Eliz…
Coverage Details
Bias Distribution
- 100% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
